Literature DB >> 12081336

Hospital prevalence of pulmonary tuberculosis and co-infection with human immunodeficiency virus in Ilorin: a review of nine years (1991-1999).

A K Salami1, P O Oluboyo.   

Abstract

This is a hospital based retrospective study that determines the prevalence of pulmonary tuberculosis (PTB) and seroprevalence of Human Immunodeficiency Virus (HIV) infection amongst PTB cases. The study was over a nine year period. The annual distribution of all PTB and PTB/HIV co-infected cases were estimated, so was the annual distribution of all medical cases seen over the same period. A total of 104,240 medical cases were seen, out of which 9697 were confirmed PTB. This gives a prevalence rate of 9.2%. Their sex ratio was M:F 1.3:1 and about 81.6% of them were between 15-54 years of age. Only 189 out of 1496 cases of PTB screened for HIV antibody were seropositive giving a seroprevalence rate of 12.6%. The annual distribution of PTB/HIV co-infection showed a rising trend from only one case in 1991 to 20 cases in 1999. Majority of those who were seropositive were traders, housewives and drivers.

Entities:  

Mesh:

Year:  2002        PMID: 12081336

Source DB:  PubMed          Journal:  West Afr J Med        ISSN: 0189-160X


  3 in total

1.  Medicinal plants used for the treatment of tuberculosis by Bapedi traditional healers in three districts of the Limpopo Province, South Africa.

Authors:  Sebua Silas Semenya; Alfred Maroyi
Journal:  Afr J Tradit Complement Altern Med       Date:  2012-12-31

2.  Treatment Outcome of Tuberculosis Patients Registered at DOTS Centre in Ogbomoso, Southwestern Nigeria: A 4-Year Retrospective Study.

Authors:  Olarewaju Sunday; Olanrewaju Oladimeji; Folorunso Ebenezer; Babatunde Akintunde; Temitayo-Oboh Abiola; Abdulsalam Saliu; Oluwatoyin Abiodun
Journal:  Tuberc Res Treat       Date:  2014-09-28

3.  Patterns of delays amongst pulmonary tuberculosis patients in Lagos, Nigeria.

Authors:  Olumuyiwa O Odusanya; Joseph O Babafemi
Journal:  BMC Public Health       Date:  2004-05-29       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.